Full Text View
Tabular View
Study Results
Related Studies
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
This study has been completed.
Study NCT00267956   Information provided by Centocor, Inc.

First Received on December 20, 2005.   Last Updated on September 11, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Psoriatic Arthritis
Additional conditions recognized in this trial
Arthritis
Arthritis, Psoriatic
More general conditions related to this trial
Bone Diseases
Joint Diseases
Musculoskeletal Diseases
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Spinal Diseases
Spondylarthritis
Spondylarthropathies
Spondylitis
Interventions listed in this trial
CNTO 1275 63 mg
Placebo
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Centocor, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services